Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer

Thorax

Volumn 66, Issue 4, 2011, Pages 287-293

  Wisnivesky, Juan P ^a   Arciniega, Jacqueline ^a   Mhango, Grace ^a   Mandeli, John ^a   Halm, Ethan A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GERIATRIC PATIENT; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE RATIO; LYMPHATIC SYSTEM EXAMINATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION;

EID: 79953005546     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.148601     Document Type: Article

References (35)

1. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-23. (Pubitemid 27260108)
2. Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 2001;19:555-61. (Pubitemid 32416603)
3. van Rens MT, de la Riviere AB, Elbers HR, et al. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000;117:374-9. (Pubitemid 30111585)
4. van Velzen E, Snijder RJ, Brutel de la Riviere A, et al. Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. Ann Thorac Surg 1997;63:1436-40. (Pubitemid 27239739)
5. Martini N, Flehinger BJ, Nagasaki F, et al. Prognostic significance of N1 disease in carcinoma of the lung. J Thorac Cardiovasc Surg 1983;86:646-53. (Pubitemid 14228786)
6. Marra A, Hillejan L, Zaboura G, et al. Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg 2003;125:543-53. (Pubitemid 36373900)
7. Osaki T, Nagashima A, Yoshimatsu T, et al. Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer 2004;43:151-7. (Pubitemid 38114743)
8. Sayar A, Turna A, Kilicgun A, et al. Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung. Eur J Cardiothorac Surg 2004;25:434-8. (Pubitemid 38340583)
9. Bria E, Milella M, Sperduti I, et al. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer 2009;66:365-71.
10. Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg 2008;85:211-15. (Pubitemid 350265823)
11. Fujimoto T, Cassivi SD, Yang P, et al. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival. J Thorac Cardiovasc Surg 2006;132:499-506. (Pubitemid 44278877)
12. Lee HY, Choi HJ, Park KJ, et al. Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol 2007;14:1712-17.
13. Vinh-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res 2004;6:R680-8.
14. Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003;10:1077-85. (Pubitemid 40486832)
15. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003;169:943-5. (Pubitemid 36188130)
16. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706-12. (Pubitemid 46211514)
17. Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17:584-90. (Pubitemid 47096709)
18. Goldstraw P, ed. Staging Manual in Thoracic Oncology. Orange Park FL: Editorial Rx Press, 2009.
19. Greenstein AJ, Litle VR, Swanson SJ, et al. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg 2008;206:239-46.
20. Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002;40(8 Suppl):IV-49-54.
21. Wisnivesky JP, Halm E, Bonomi M, et al. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med 2010;181:264-9.
22. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40(8 Suppl):IV-55-61.
23. Ludwig MS, Goodman M, Miller DL, et al. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest 2005;128:1545-50. (Pubitemid 41324445)
24. Khan OA, Fitzgerald JJ, Field ML, et al. Histological determinants of survival in completely resected T1-2N1M0 nonsmall cell cancer of the lung. Ann Thorac Surg 2004;77:1173-8. (Pubitemid 38452341)
25. Luzzi L, Voltolini L, Campione A, et al. Pneumonectomy vs lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival? J Cardiovasc Surg (Torino) 2003;44:119-23.
26. The NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer (Version V.I.2010) http://www.nccn.org/professionals/physician-gls/f- guidelines.asp (accessed 7 Jul 2010).
27. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28:35-42.
28. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. (Pubitemid 44200650)
29. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
30. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-9.
31. Varlotto JM, Recht A, Nikolov M, et al. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer 2009;115:851-8.
32. Percy C, Stanek E 3rd, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981;71:242-50. (Pubitemid 11146407)
33. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol 2007;25:1705-12.
34. Anon. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-63.
35. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.